Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00519389

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)

Sponsor: Novavax

Conditions Pandemic Influenza

Interventions H5N1 VLP Vaccine Placebo

Updated 7 times since 2017 Last updated: Jun 12, 2013 Started: Jul 31, 2007 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00519389, this PHASE1/PHASE2 trial focuses on Pandemic Influenza and remains completed. Sponsored by Novavax, it has been updated 7 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novavax

Data source: Novavax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States